Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 9/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | CTSE | P14091 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | PLD1 | Q13393 | 4/20 | 0.41 |
| ▸ | PLD2 | O14939 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5563268 | 0.89 | SLC6A9 (0.52) | SLC6A9GPR119PLD1PLD2 | |
| SCHEMBL939206 | 0.89 | GPR119 (0.43) | SLC6A9GPR119 | |
| SCHEMBL1138300 | 0.88 | SLC6A9 (0.54) | SLC6A9PLD1PLD2 | |
| SCHEMBL4334410 | 0.88 | SLC6A9 (0.53) | SLC6A9 | |
| SCHEMBL5557626 | 0.86 | SLC6A9 (0.53) | SLC6A9GPR119PLD1PLD2 | |
| SCHEMBL4331180 | 0.86 | SLC6A9 (0.41) | SLC6A9PLD1PLD2 | |
| SCHEMBL14058697 | 0.84 | SLC6A9 (0.54) | SLC6A9 | |
| SCHEMBL14057437 | 0.82 | SLC6A9 (0.48) | SLC6A9 | |
| SCHEMBL14057977 | 0.77 | SLC6A9 (0.48) | SLC6A9GPR119 | |
| SCHEMBL15437748 | 0.77 | DDB1 (0.44) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716147-B1 | DIAZA-SPIROPIPERIDINE DERIVATIVES AS INHIBITORS OF GLYCINE TRANSPORTER 1 AND GLYCINE TRANSPORTER 2 | HOFFMANN LA ROCHE (CH) | 2007-11-14 | — | — | EP | disclosed |
| US-7265126-B2 | Diaza-spiropiperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1716147-A1 | DIAZA-SPIROPIPERIDINE DERIVATIVES AS INHIBITORS OF GLYCINE TRANSPORTER 1 AND GLYCINE TRANSPORTER 2 | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005068462-A1 | DIAZA-SPIROPIPERIDINE DERIVATIVES AS INHIBITORS OF TRANSPORTER 1 AND GLYCINE TRANSPORTER 2 | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-28 | — | — | WO | disclosed |
| US-20050154000-A1 | Diaza-spiropiperidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154000-A1 | Diaza-spiropiperidine derivatives | AVPR1A, AVPR1B, QDPR | SLC6A9 1752/4885ALDH1A1 111/4885BACE1 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.